🚀 The labs aim to enhance the development of injectable products. They support formulation studies, stability evaluations, and more.
🧪 These facilities also ensure compliance with cGMP standards, providing thorough sterility and quality testing.
💼 This expansion reflects Recipharm’s commitment to delivering robust pharmaceutical solutions globally.
Introduction:
Recipharm, a prominent contract development and manufacturing organization (CDMO), has recently enhanced its operational capabilities by inaugurating parenteral development and sterility laboratories at its Bengaluru site in India. This strategic investment aims to reinforce Recipharm’s commitment to offering comprehensive solutions in the development of sterile pharmaceuticals.
- The newly established parenteral development laboratory is specialized for the rapid development of generic and proof-of-concept injectable products.
- The facility is equipped for formulation studies, analytical testing, and stability evaluations, ensuring robust product development pathways.
- Utilizing Quality by Design (QbD) principles, the laboratory supports crucial early-stage activities involved in drug formulation.
- The expansion includes enhanced sterility testing capabilities and particle analysis to ensure compliance with cleanroom standards and product release quality.
- This investment is indicative of Recipharm’s broader strategy to provide end-to-end solutions, emphasizing both scientific rigor and regulatory compliance in sterile drug manufacturing.
Conclusion:
The opening of the parenteral development and sterility laboratories in Bengaluru marks a significant milestone for Recipharm, positioning the company to offer improved services in sterile pharmaceutical development. This development not only responds to the increasing demand for high-quality injectables but also enhances Recipharm’s competitive edge in global markets, ultimately benefiting partners and stakeholders in the pharmaceutical industry.
